Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial-Reference-Cited by-同舟云学术

Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

Published:2019-12-04 Issue:1 Volume:147 Page:160-169
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lambertini Matteo¹²^ORCID,Poggio Francesca³,Bruzzone Marco⁴,Conte Benedetta³,Bighin Claudia³,Azambuja Evandro⁵,Giuliano Mario⁶,De Laurentiis Michele⁷,Cognetti Francesco⁸⁹,Fabi Alessandra⁸⁹,Bisagni Giancarlo¹⁰,Durando Antonio¹¹,Turletti Anna¹²,Urracci Ylenia¹³,Garrone Ornella¹⁴,Puglisi Fabio¹⁵¹⁶,Montemurro Filippo¹⁷,Ceppi Marcello⁴,Del Mastro Lucia²³,

Affiliation:

1. Department of Medical OncologyU.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino Genoa Italy

2. Department of Internal Medicine and Medical Specialties (DiMI)School of Medicine, University of Genova Genoa Italy

3. Department of Medical OncologyBreast Unit, IRCCS Ospedale Policlinico San Martino Genoa Italy

4. Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino Genoa Italy

5. Department of Medical OncologyInstitut Jules Bordet and l'Université Libre de Bruxelles (U.L.B) Brussels Belgium

6. Department of Clinical Medicine and SurgeryUniversity of Naples “Federico II” Naples Italy

7. Medical Oncology, Istituto Nazionale Tumori‐IRCCS Fondazione Pascale Naples Italy

8. La Sapienza University Rome Italy

9. Department of Medical Oncology 1Istituto Nazionale Tumori Regina Elena Rome Italy

10. Department of Medical OncologyAzienda Unità Sanitaria Locale – IRCCS di Reggio Emilia Reggio Emilia Italy

11. Breast Unit, Azienda Ospedaliera Universitaria Città della Salute e delle Scienze Torino Italy

12. Medical Oncology, Martini Hospital ASL Città’ di Torino Italy

13. Department of Medical OncologyHospital Businco Cagliari Italy

14. Breast Unit, Medical Oncology, Azienda Ospedaliera S. Croce e Carle, Ospedale di Insegnamento Cuneo Italy

15. Unit of Medical Oncology and Cancer Prevention, IRCCS Centro di Riferimento Oncologico Aviano‐National Cancer Institute Aviano (Udine) Italy

16. Medical Oncology, Department of MedicineUniversity of Udine Udine Italy

17. Day Hospital Oncologico Multidisciplinare, Istituto di Candiolo, FPO‐IRCCS Candiolo Torino Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32789

Reference24 articles.

1. Adjuvant systemic therapy in breast cancer: quo vadis?

2. Breast Cancer Treatment

3. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials

4. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

5. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy;The Breast;2024-06

2. Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis;Oncology Letters;2023-11-07

3. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper;Clinical Breast Cancer;2023-10

4. Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy;Molecular Oncology;2023-04-24

5. Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba;Cancer Treatment and Research Communications;2023